Atorvastatin and telmisartan do not reduce nasopharyngeal carriage of SARS-CoV-2 in mild or moderate COVID-19 in a phase IIb randomized controlled trial by Fabrice Bonnet, Adama Doumbia, Vanessa Machault, Frederic Nogbou Ello, Pantxika Bellecave, Corine Bernice Akpovo, Baba Toumany Sidibe, Laura Fernandez, Antoine Kouamé, Edgard Adjogoua, Mireille Dosso, Serge Niangoran, Valérie Journot, Serge Paul Eholié

Get full text